• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by CAI International, Inc. (Amendment)

    4/30/21 9:14:28 AM ET
    $CAI
    Medical Specialities
    Health Care
    Get the next $CAI alert in real time by email
    SC 13D/A 1 d181925dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D/A

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENT FILED PURSUANT

    TO RULE 13d-1(a) AND AMENDMENTS THERETO

    FILED PURSUANT TO RULE 13d-2(a)

    (AMENDMENT NO. 4)1

     

     

    CAI International, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    12477X106

    (CUSIP Number)

    Weiss Asset Management LP

    c/o Georgiy Nikitin

    222 Berkeley St., 16th Floor

    Boston, MA 02116

    (617) 778-7725

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    April 29, 2021**

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13(d)-1(g), check the following box.  ☐

     

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

    (Continued on following pages)

    (Page 1 of 7 Pages)

      **

    Please see Item 5.

     

    1

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.  12477X106   13D/A   Page 2 of 7 Pages

     

      1   

    NAMES OF REPORTING PERSONS.

     

    Weiss Asset Management LP

    BIP GP LLC

    WAM GP LLC

    Andrew M. Weiss Ph.D.

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    SOURCE OF FUNDS

     

    WC

      5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Weiss Asset Management LP is a Delaware limited partnership.

    BIP GP LLC is a Delaware limited liability company.

    WAM GP LLC is a Delaware limited liability company.

    Andrew M. Weiss is a United States citizen.

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    PERSON

    WITH

     

         7    

    SOLE VOTING POWER

     

    Weiss Asset Management LP — 0 shares

    BIP GP LLC — 0 shares

    WAM GP LLC — 0 shares

    Andrew M. Weiss — 0 shares

         8   

    SHARED VOTING POWER

     

    Weiss Asset Management LP — 1,056,561 **

    BIP GP LLC — 688,045 **

    WAM GP LLC — 1,056,561 **

    Andrew M. Weiss — 1,056,561 **

         9   

    SOLE DISPOSITIVE POWER

     

    Weiss Asset Management LP — 0 shares

    BIP GP LLC — 0 shares

    WAM GP LLC — 0 shares

    Andrew M. Weiss — 0 shares

       10   

    SHARED DISPOSITIVE POWER

     

    Weiss Asset Management LP — 1,056,561 **

    BIP GP LLC — 688,045**

    WAM GP LLC — 1,056,561 **

    Andrew M. Weiss — 1,056,561 **

     

    **

    Please see Item 5.


    CUSIP No.  12477X106   13D/A   Page 3 of 7 Pages

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    Weiss Asset Management LP — 1,056,561 **

    BIP GP LLC — 688,045**

    WAM GP LLC — 1,056,561 **

    Andrew M. Weiss — 1,056,561 **

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    Weiss Asset Management LP — 6.11% **

    BIP GP LLC — 3.98% **

    WAM GP LLC — 6.11% **

    Andrew M. Weiss — 6.11% **

    14  

    TYPE OF REPORTING PERSON

     

    Weiss Asset Management LP — IA, PN

    BIP GP LLC — HC, OO

    WAM GP LLC — HC, OO

    Andrew M. Weiss — HC, IN

    This Amendment No. 4 (this “Amendment”) to Schedule 13D amends the Schedule 13D initially filed on August 23, 2019, (as amended prior to the date hereof, the “Prior Schedule 13D” and, as so amended by this Amendment, the “Schedule 13D”) with respect to the items set forth below. Capitalized terms used without definition in this Amendment have the meanings assigned to them in the Prior Schedule 13D.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    The Shares were acquired in open market purchases for an aggregate of approximately $24.74 million cash by: (i) BIP of which BIP GP LLC is the sole General Partner and (ii) Brookdale Global Opportunity Fund, a Cayman exempted company (“BGO” and together with BIP, the “Funds”), for which Weiss Asset Management LP acts as the Investment Manager.

    The source of such funds was the working capital of the Funds.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    The percentages set forth in Row 13 of the cover page and in this Item 5 have been calculated based on 17,304,111 Shares of the Issuer’s Common Stock issued and outstanding as of April 8, 2021, as reported in the Issuer’s Proxy Statement filed on April 21, 2021. Each of the Reporting Persons disclaims beneficial ownership of all of the Shares, except to the extent of its or his pecuniary interest therein, and the filing of this Schedule 13D shall not be deemed an admission of beneficial ownership of any Shares for any purpose.


    CUSIP No.  12477X106   13D/A   Page 4 of 7 Pages

     

    (a) and (b)     688,045 Shares, representing approximately 3.98% of the outstanding shares of the Issuer, are held by BIP. BIP GP LLC is the general partner of BIP. Weiss Asset Management LP is the investment manager of BIP. Dr. Weiss is the managing member of each of BIP GP LLC and WAM GP LLC and in such capacity has the power to vote and dispose of such Shares.

    368,516 Shares, representing approximately 2.13% of the outstanding shares of the Issuer, are held by BGO. Weiss Asset Management LP is the investment manager of BGO. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares.

    See Rows 7-13 of the cover page above for the aggregate number and percentage beneficially owned by each of the Reporting Persons.

    (c)     The transactions in the Issuer’s Common Stock engaged in by BIP and BGO during the past 60 days are set forth on Schedule A hereto, which is hereby incorporated herein by reference. All of such transactions were open-market purchases.

    (d)     Other than the Funds that directly hold the securities of the Issuer, and except as set forth in this Item 5, no other person is known to have the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale, of the Shares.

    (e)     Not applicable.


    CUSIP No.  12477X106   13D/A   Page 5 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete, and correct.

    April 30, 2021

     

    WEISS ASSET MANAGEMENT LP

    BY: /S/ GEORGIY NIKITIN

    GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
    BIP GP LLC

    BY: /S/ GEORGIY NIKITIN

    GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
    WAM GP LLC

    BY: /S/ GEORGIY NIKITIN

    GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER

    BY: /S/ GEORGIY NIKITIN

    ATTORNEY-IN-FACT FOR ANDREW WEISS**

     

    **

    Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on January 25, 2017 in respect of its holding in Quinpario Acquisition Corp. 2.


    CUSIP No.  12477X106   13D/A   Page 6 of 7 Pages

     

    Schedule A

    Transactions Effected in Last 60 Days

    Transactions by BIP:

     

    Date

      

    Type of Transaction

      

    Number of Shares

       Purchase Price
                Per Share ($)             
     

    4/29/2021

       Open Market Sale    7964    $ 43.62  

    4/28/2021

       Open Market Sale    3132    $ 45.51  

    4/27/2021

       Open Market Sale    12243    $ 44.45  

    4/27/2021

       Open Market Sale    10419    $ 44.64  

    4/22/2021

       Open Market Sale    1197    $ 41.66  

    4/22/2021

       Open Market Sale    3256    $ 41.12  

    4/21/2021

       Open Market Sale    7878    $ 42.31  

    4/20/2021

       Open Market Sale    130    $ 43.88  

    4/19/2021

       Open Market Sale    2645    $ 44.34  

    4/16/2021

       Open Market Sale    2690    $ 44.19  

    4/15/2021

       Open Market Sale    5878    $ 45.26  

    4/14/2021

       Open Market Sale    4194    $ 46.26  

    4/13/2021

       Open Market Sale    7552    $ 44.56  

    4/12/2021

       Open Market Sale    2318    $ 45.20  

      4/9/2021

       Open Market Sale    1357    $ 43.55  

      4/8/2021

       Open Market Sale    1111    $ 43.93  

      4/7/2021

       Open Market Sale    5246    $ 45.12  

      4/6/2021

       Open Market Sale    2389    $ 45.25  

      4/5/2021

       Open Market Sale    2617    $ 47.22  

      4/5/2021

       Open Market Sale    5555    $ 46.90  

      4/1/2021

       Open Market Sale    2547    $ 45.08  

    3/31/2021

       Open Market Sale    725    $ 46.32  

    3/31/2021

       Open Market Sale    13024    $ 45.81  

    3/30/2021

       Open Market Sale    2219    $ 45.55  

    3/30/2021

       Open Market Sale    26048    $ 45.30  

    3/29/2021

       Open Market Sale    2182    $ 46.77  

    3/26/2021

       Open Market Sale    781    $ 46.85  

    Transactions by BGO:

     

    Date

      

    Type of Transaction

      

    Number of Shares

       Purchase Price
                Per Share ($)             
     

    4/29/2021

       Open Market Sale    4265    $ 43.62  

    4/28/2021

       Open Market Sale    1678    $ 45.51  

    4/27/2021

       Open Market Sale    6558    $ 44.45  

    4/27/2021

       Open Market Sale    5581    $ 44.64  

    4/22/2021

       Open Market Sale    641    $ 41.66  

     


    CUSIP No.  12477X106   13D/A   Page 7 of 7 Pages

     

    4/22/2021

       Open Market Sale    1744    $                           41.12  

    4/21/2021

       Open Market Sale    4219    $ 42.31  

    4/20/2021

       Open Market Sale    70    $ 43.88  

    4/19/2021

       Open Market Sale    1416    $ 44.34  

    4/16/2021

       Open Market Sale    1440    $ 44.19  

    4/15/2021

       Open Market Sale    3148    $ 45.26  

    4/14/2021

       Open Market Sale    2246    $ 46.26  

    4/13/2021

       Open Market Sale    4045    $ 44.56  

    4/12/2021

       Open Market Sale    1242    $ 45.20  

      4/9/2021

       Open Market Sale    731    $ 43.55  

      4/8/2021

       Open Market Sale    595    $ 43.93  

      4/7/2021

       Open Market Sale    2810    $ 45.12  

      4/6/2021

       Open Market Sale    1280    $ 45.25  

      4/5/2021

       Open Market Sale    1402    $ 47.22  

      4/5/2021

       Open Market Sale    2975    $ 46.90  

      4/1/2021

       Open Market Sale    1364    $ 45.08  

    3/31/2021

       Open Market Sale    388    $ 46.32  

    3/31/2021

       Open Market Sale    6976    $ 45.81  

    3/30/2021

       Open Market Sale    1189    $ 45.55  

    3/30/2021

       Open Market Sale    13952    $ 45.30  

    3/29/2021

       Open Market Sale    1169    $ 46.77  

    3/26/2021

       Open Market Sale    419    $ 46.85  
    Get the next $CAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAI

    DatePrice TargetRatingAnalyst
    6/2/2026Peer Perform
    Wolfe Research
    4/13/2026$28.00Buy
    Jefferies
    4/10/2026$21.00Neutral
    Piper Sandler
    4/1/2026$27.00Buy
    Goldman
    2/17/2026$26.00Outperform
    Robert W. Baird
    12/2/2025$28.00Hold
    Canaccord Genuity
    7/14/2025$31.00Buy
    BofA Securities
    7/14/2025$31.00Overweight
    Analyst
    More analyst ratings

    $CAI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.

    SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)

    5/12/26 4:30:03 PM ET
    $CAI
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.

    SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)

    5/12/26 10:47:25 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Caris Life Sciences Inc.

    10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)

    5/8/26 4:13:40 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Vacirca Jeff L bought $501,426 worth of shares (31,050 units at $16.15), increasing direct ownership by 167% to 49,671 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    5/12/26 8:22:31 AM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel bought $100,793 worth of shares (4,184 units at $24.09) (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:12:42 AM ET
    $CAI
    Medical Specialities
    Health Care

    President Spetzler David Baxley bought $9,540 worth of shares (400 units at $23.85), increasing direct ownership by 0.09% to 460,777 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:11:33 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Caris Life Sciences

    Wolfe Research resumed coverage of Caris Life Sciences with a rating of Peer Perform

    6/2/26 8:32:11 AM ET
    $CAI
    Medical Specialities
    Health Care

    Jefferies initiated coverage on Caris Life Sciences with a new price target

    Jefferies initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $28.00

    4/13/26 8:51:07 AM ET
    $CAI
    Medical Specialities
    Health Care

    Piper Sandler initiated coverage on Caris Life Sciences with a new price target

    Piper Sandler initiated coverage of Caris Life Sciences with a rating of Neutral and set a new price target of $21.00

    4/10/26 8:31:01 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

    Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphomaIRVING, Texas, May 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today launched "Behind the Diagnosis," a new campaign that spotlights patients whose care has been targeted and personalized by Caris' comprehensive molecular profiling and AI-powered precision medicine. The inaugural story features Erika Rios, who was diagnosed prior to Caris testing, with stage 4 metastatic triple-nega

    5/26/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

    The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types IRVING, Texas, May 15, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the publication of a Caris‑led study in The Oncologist demonstrating the ability of the Caris Lookback Program to proactively identify previously-profiled patients who become eligible for newly approved targeted therapies. Molecular profiling reports from most

    5/15/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Real-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare Opportunities

    AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifyi

    5/13/26 8:30:00 AM ET
    $CAI
    $MDAI
    $NNOX
    Medical Specialities
    Health Care
    Medical/Dental Instruments
    Medical Electronics

    $CAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Poste George was granted 1,600 shares, increasing direct ownership by 10% to 17,729 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/2/26 5:44:17 PM ET
    $CAI
    Medical Specialities
    Health Care

    Director Knowles Jonathan Kenneth Charles was granted 1,600 shares, increasing direct ownership by 0.52% to 308,979 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/2/26 5:43:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel covered exercise/tax liability with 6,047 shares, decreasing direct ownership by 3% to 181,515 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    5/18/26 4:23:48 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CAI International, Inc. (Amendment)

    SC 13G/A - CAI International, Inc. (0001388430) (Subject)

    12/10/21 10:00:15 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    11/12/21 9:17:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    10/7/21 4:07:36 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Financials

    Live finance-specific insights

    View All

    Caris Life Sciences Reports First Quarter 2026 Financial Results

    Revenue growth of 79% driven by strong performance in molecular profiling servicesIRVING, Texas, May 7, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (NASDAQ:CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial HighlightsReported total revenue of $216.2 million, an increase of 79% over the corresponding prior year period.Completed approximately 52,800 clinical therapy selection cases, an increase of approximately 15% over the corres

    5/7/26 4:05:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

    IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Thursday, May 7, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/A replay of the webcast will be available shortly after the conclusion

    4/20/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

    IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th

    2/9/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care